The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

BACKGROUND: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lucas, David M., Alinari, Lapo, West, Derek A., Davis, Melanie E., Edwards, Ryan B., Johnson, Amy J., Blum, Kristie A., Hofmeister, Craig C., Freitas, Michael A., Parthun, Mark R., Wang, Dasheng, Lehman, Amy, Zhang, Xiaoli, Jarjoura, David, Kulp, Samuel K., Croce, Carlo M., Grever, Michael R., Chen, Ching-Shih, Baiocchi, Robert A., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2010
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2880605/
https://ncbi.nlm.nih.gov/pubmed/20532179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0010941
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados